Clave Capital

Clave Capital is an independent Spanish venture capital and alternative asset management firm specializing in early-stage investments, with a strong focus on healthcare, medtech, biotech, eHealth, and nutrition. Through its flagship fund Clave Innohealth (target size €80M), it supports technology transfer projects from research organizations and startups across Spain. The firm has over two decades of experience and manages more than €90 million across multiple funds. About half of its current portfolio consists of health sector projects[1][3][4][5][6].

Recent investments include D-Sight (developing drugs for diabetic retinopathy and glaucoma) and ADmit Therapeutics (early detection technology for Alzheimer's disease)[7][9]. Clave provides both capital and active management support to portfolio companies[6].

The firm collaborates with public institutions like CDTI Innvierte as well as private investors linked to the health sector[6][8]. It also partners with innovation hubs such as Barcelona Health Hub to accelerate healthcare technology transfer[8].

Its investment model emphasizes disruptive innovation but also supports incremental advances that address unmet medical needs in the bio-health field.

Portfolio breadth includes at least 21 active healthtech companies from universities/research centers/hospitals[6], with plans for 30–35 investments via the Innohealth fund.

Key people include Santiago Lozano (Fund Director), Giacomo De Simone (Head of Barcelona delegation), Alberto Bermejo (Director of Funds), Antonio Tornero (Investment Manager), Cesar Mendoza (Director of Funds), Fernando Frauca Amorena (Partner)[1][6].

Headquarters are in Pamplona, Spain; additional offices are located in Madrid and at the Barcelona Science Park[1][2][5][6].

Estimated employees number between 10–19; revenue estimated at $1M–$5M USD annually[2].

Website URL is clave.capital.